HK1104300A1 - Dimeric iap inhibitors - Google Patents

Dimeric iap inhibitors

Info

Publication number
HK1104300A1
HK1104300A1 HK07112782.0A HK07112782A HK1104300A1 HK 1104300 A1 HK1104300 A1 HK 1104300A1 HK 07112782 A HK07112782 A HK 07112782A HK 1104300 A1 HK1104300 A1 HK 1104300A1
Authority
HK
Hong Kong
Prior art keywords
iap inhibitors
dimeric iap
dimeric
inhibitors
iap
Prior art date
Application number
HK07112782.0A
Other languages
English (en)
Inventor
Stephen M Condon
Matthew G Laporte
Yijun Deng
Susan R Rippin
Original Assignee
Tetralogic Pharm Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=36636946&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1104300(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Tetralogic Pharm Corp filed Critical Tetralogic Pharm Corp
Publication of HK1104300A1 publication Critical patent/HK1104300A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06008—Dipeptides with the first amino acid being neutral
    • C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
    • C07K5/0606—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing heteroatoms not provided for by C07K5/06086 - C07K5/06139, e.g. Ser, Met, Cys, Thr
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
HK07112782.0A 2005-02-25 2007-11-23 Dimeric iap inhibitors HK1104300A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US65620105P 2005-02-25 2005-02-25
US66834405P 2005-04-05 2005-04-05
US69211105P 2005-06-20 2005-06-20
US70664905P 2005-08-09 2005-08-09
US72985305P 2005-10-25 2005-10-25
PCT/US2006/007068 WO2006091972A2 (en) 2005-02-25 2006-02-27 Dimeric iap inhibitors

Publications (1)

Publication Number Publication Date
HK1104300A1 true HK1104300A1 (en) 2008-01-11

Family

ID=36636946

Family Applications (2)

Application Number Title Priority Date Filing Date
HK07112782.0A HK1104300A1 (en) 2005-02-25 2007-11-23 Dimeric iap inhibitors
HK08108137.9A HK1118044A1 (en) 2005-02-25 2008-07-23 Dimeric iap inhibitors iap

Family Applications After (1)

Application Number Title Priority Date Filing Date
HK08108137.9A HK1118044A1 (en) 2005-02-25 2008-07-23 Dimeric iap inhibitors iap

Country Status (17)

Country Link
US (7) US7517906B2 (xx)
EP (2) EP2385038A1 (xx)
JP (1) JP5198880B2 (xx)
KR (1) KR101317661B1 (xx)
CN (1) CN103083644B (xx)
AU (1) AU2006216450C1 (xx)
BR (1) BRPI0607988A2 (xx)
CA (1) CA2598995C (xx)
CY (1) CY1115972T1 (xx)
DK (1) DK1851200T3 (xx)
EA (1) EA012810B1 (xx)
ES (1) ES2456671T3 (xx)
HK (2) HK1104300A1 (xx)
IL (1) IL185454A (xx)
MX (1) MX2007010371A (xx)
PL (1) PL1851200T3 (xx)
WO (1) WO2006091972A2 (xx)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
DK1836201T4 (da) * 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
CN103083644B (zh) * 2005-02-25 2014-05-28 泰特拉洛吉克药业公司 Iap二聚体抑制剂
EP1883627B1 (en) * 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
US20100256046A1 (en) * 2009-04-03 2010-10-07 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
AU2006308453B9 (en) * 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
EP1973899A4 (en) 2005-12-19 2010-10-20 Genentech Inc HEMMER OF IAP
TWI504597B (zh) 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
NZ572836A (en) * 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
AR064235A1 (es) 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
AU2007276760B2 (en) * 2006-07-24 2012-01-19 Tetralogic Pharmaceuticals Corporation Dimeric IAP antagonists
WO2008014238A2 (en) * 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008014240A2 (en) 2006-07-24 2008-01-31 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
US20100056495A1 (en) * 2006-07-24 2010-03-04 Tetralogic Pharmaceuticals Corporation Dimeric iap inhibitors
WO2008079735A1 (en) 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
MX2009010667A (es) * 2007-04-12 2010-02-24 Joyant Pharmaceuticals Inc Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.
NZ580226A (en) * 2007-04-30 2012-11-30 Genentech Inc Dimer compounds as inhibitors of iap
WO2008144925A1 (en) * 2007-05-30 2008-12-04 Aegera Therapeutics Inc. Iap bir domain binding compounds
CA2712604A1 (en) * 2008-01-24 2009-07-30 Tetralogic Pharmaceutical Corporation Iap inhibitors
WO2009136290A1 (en) * 2008-05-05 2009-11-12 Aegera Therapeutics, Inc. Functionalized pyrrolidines and use thereof as iap inhibitors
US9750729B2 (en) 2008-05-16 2017-09-05 Dana-Farber Cancer Institute, Inc. Immunomodulation by IAP inhibitors
EP2310402A1 (en) * 2008-06-27 2011-04-20 Aegera Therapeutics Inc. Bridged secondary amines and use thereof as iap bir domain binding compounds
CA2730448A1 (en) 2008-08-02 2010-02-11 Genentech, Inc. Inhibitors of iap
AU2009293545A1 (en) * 2008-09-22 2010-03-25 Amgen Inc. Method of treatment
US20100317593A1 (en) * 2009-06-12 2010-12-16 Astrazeneca Ab 2,3-dihydro-1h-indene compounds
US8283372B2 (en) * 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic
EP2784076A1 (en) * 2009-10-28 2014-10-01 Joyant Pharmaceuticals, Inc. Dimeric SMAC mimetics
SG10201501095WA (en) 2010-02-12 2015-04-29 Pharmascience Inc Iap bir domain binding compounds
UY33236A (es) 2010-02-25 2011-09-30 Novartis Ag Inhibidores dimericos de las iap
UY33794A (es) 2010-12-13 2012-07-31 Novartis Ag Inhibidores diméricos de las iap
GB201106817D0 (en) 2011-04-21 2011-06-01 Astex Therapeutics Ltd New compound
US20140243276A1 (en) 2011-09-30 2014-08-28 Tetralogic Pharmaceuticals Corporation Smac mimetic (birinapant) for use in the treatment of proliferative diseases (cancer)
US20130196927A1 (en) * 2012-01-27 2013-08-01 Christopher BENETATOS Smac Mimetic Therapy
CA2930030A1 (en) * 2012-11-09 2014-05-15 Ensemble Therapeutics Corporation Macrocyclic compounds for inhibition of inhibitors of apoptosis
WO2014121178A1 (en) * 2013-02-04 2014-08-07 Tetralogic Pharmaceuticals Corp. Smac mimetic method of treatment
JP6785653B2 (ja) 2013-06-25 2020-11-18 ザ・ウォルター・アンド・エリザ・ホール・インスティテュート・オブ・メディカル・リサーチ 細胞内感染の処置方法
GB201311888D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compounds
GB201311891D0 (en) 2013-07-03 2013-08-14 Glaxosmithkline Ip Dev Ltd Novel compound
WO2015017520A1 (en) * 2013-07-30 2015-02-05 Tetralogic Pharmaceuticals Corp. Method of treatment
WO2015092420A1 (en) 2013-12-20 2015-06-25 Astex Therapeutics Limited Bicyclic heterocycle compounds and their uses in therapy
WO2015187998A2 (en) 2014-06-04 2015-12-10 Sanford-Burnham Medical Research Institute Use of inhibitor of apoptosis protein (iap) antagonists in hiv therapy
CN104030964B (zh) * 2014-06-05 2016-06-29 天津科技大学 双吲哚类化合物及合成方法
WO2016079527A1 (en) 2014-11-19 2016-05-26 Tetralogic Birinapant Uk Ltd Combination therapy
WO2016097773A1 (en) 2014-12-19 2016-06-23 Children's Cancer Institute Therapeutic iap antagonists for treating proliferative disorders
US20170327469A1 (en) 2015-01-20 2017-11-16 Arvinas, Inc. Compounds and methods for the targeted degradation of androgen receptor
CN107428734A (zh) 2015-01-20 2017-12-01 阿尔维纳斯股份有限公司 用于雄激素受体的靶向降解的化合物和方法
WO2016197114A1 (en) 2015-06-05 2016-12-08 Arvinas, Inc. Tank-binding kinase-1 protacs and associated methods of use
US10772962B2 (en) 2015-08-19 2020-09-15 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of bromodomain-containing proteins
WO2017186147A1 (zh) 2016-04-27 2017-11-02 南京明德新药研发股份有限公司 作为新型二价iap拮抗剂的苯并咪唑联吲哚化合物
US10398702B2 (en) * 2016-05-09 2019-09-03 Hoffmann-La Roche Inc. Dimeric compounds
CA3042260C (en) 2016-11-01 2023-10-03 Arvinas, Inc. Tau-protein targeting protacs and associated methods of use
BR112019011200B1 (pt) 2016-12-01 2021-12-28 Arvinas Operations, Inc Derivados de tetrahidronaftaleno e tetrahidroisoquinolina como degradadores do receptor de estrogênio
US11173211B2 (en) 2016-12-23 2021-11-16 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
US10806737B2 (en) 2016-12-23 2020-10-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
EP3559002A4 (en) 2016-12-23 2021-02-17 Arvinas Operations, Inc. CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE
JP2020504741A (ja) 2016-12-23 2020-02-13 アルビナス・オペレーションズ・インコーポレイテッドＡｒｖｉｎａｓ Ｏｐｅｒａｔｉｏｎｓ， Ｉｎｃ． Ｒａｆ（急速進行性線維肉腫）ポリペプチドの標的分解のための化合物および方法
US11191741B2 (en) 2016-12-24 2021-12-07 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
WO2018140809A1 (en) 2017-01-26 2018-08-02 Arvinas, Inc. Modulators of estrogen receptor proteolysis and associated methods of use
US11065231B2 (en) 2017-11-17 2021-07-20 Arvinas Operations, Inc. Compounds and methods for the targeted degradation of interleukin-1 receptor- associated kinase 4 polypeptides
AU2019249231B2 (en) 2018-04-04 2022-04-21 Arvinas Operations, Inc. Modulators of proteolysis and associated methods of use
CN112912376A (zh) 2018-08-20 2021-06-04 阿尔维纳斯运营股份有限公司 用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
WO2021011913A1 (en) 2019-07-17 2021-01-21 Arvinas Operations, Inc. Tau-protein targeting compounds and associated methods of use
KR20220130190A (ko) 2020-01-20 2022-09-26 아스트라제네카 아베 암 치료를 위한 표피성장인자 수용체 티로신 키나제 억제제
US11957759B1 (en) 2022-09-07 2024-04-16 Arvinas Operations, Inc. Rapidly accelerated fibrosarcoma (RAF) degrading compounds and associated methods of use
WO2024133721A1 (en) 2022-12-21 2024-06-27 Step Pharma S.A.S. Combinations of ctps1 inhibitor with iap inhibitor for use in the treatment of cancer

Family Cites Families (70)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US3832253A (en) 1973-03-21 1974-08-27 Baxter Laboratories Inc Method of making an inflatable balloon catheter
DE2714880A1 (de) 1977-04-02 1978-10-26 Hoechst Ag Cephemderivate und verfahren zu ihrer herstellung
US4667014A (en) 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
CA1200416A (en) 1983-05-13 1986-02-11 Societe Des Produits Nestle S.A. Food process
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5208007A (en) 1988-11-22 1993-05-04 Board Of Regents Of The University Of Oklahoma Isotopic tracer composition and method for making and using same
JPH04167172A (ja) 1990-10-31 1992-06-15 Nec Corp ベクトルプロセッサ
ES2130406T5 (es) 1992-08-05 2003-12-16 Meito Sangyo Kk Material compuesto de pequeño diametro compuesto de carboxipolisacarido soluble en agua y oxido de hierro magnetico.
US6187557B1 (en) 1995-08-08 2001-02-13 Tularik Inc. c-IAP1 and c-IAP2: inhibitors of apoptosis
US5786173A (en) 1996-03-19 1998-07-28 Idun Pharmaceuticals, Inc. MCH4 and MCH5, apoptotic protease, nucleic acids encoding and methods of use
US6133437A (en) * 1997-02-13 2000-10-17 Apoptogen, Inc. Modulation of IAPs for the treatment of proliferative diseases
US5961955A (en) 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
US5977311A (en) 1997-09-23 1999-11-02 Curagen Corporation 53BP2 complexes
US6110691A (en) 2000-01-06 2000-08-29 Board Of Regents, The University Of Texas System Activators of caspases
US6608026B1 (en) 2000-08-23 2003-08-19 Board Of Regents, The University Of Texas System Apoptotic compounds
WO2002016418A2 (en) 2000-08-24 2002-02-28 Thomas Jefferson University An iap binding peptide or polypeptide and methods of using the same
WO2002026775A2 (en) 2000-09-29 2002-04-04 Trustees Of Princeton University Compositions and methods for regulating apoptosis
US6992063B2 (en) 2000-09-29 2006-01-31 The Trustees Of Princeton University Compositions and method for regulating apoptosis
WO2002030959A2 (en) 2000-10-13 2002-04-18 Abbott Laboratories Peptides derived from smac (diablo) and methods of use therefor
US20020160975A1 (en) 2001-02-08 2002-10-31 Thomas Jefferson University Conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO for mediating apoptosis
US20050176649A1 (en) 2001-05-31 2005-08-11 Mclendon George Iap binding peptides and assays for identifying compounds that bind iap
EP1420786A2 (en) 2001-08-23 2004-05-26 The Government of the United States of America, as represented by the Secretary, Department of Health and Human Services Methods of inhibiting formation of vascular channels and proliferation using pyridinone derivatives
CN101029080A (zh) 2001-11-21 2007-09-05 伯纳姆研究院 用于对iap抑制卡斯蛋白酶进行去阻遏的方法及组合物
US20060258581A1 (en) 2001-11-21 2006-11-16 Reed John C Methods and composition for derepressions of IAP-inhibited caspase
US20060128632A1 (en) 2002-07-02 2006-06-15 Sharma Sushil K Peptide inhibitors of smac protein binding to inhibitor of apoptosis proteins (iap)
ES2318167T3 (es) * 2002-07-15 2009-05-01 The Trustees Of Princeton University Compuestos de union a iap.
US20080199439A1 (en) * 2003-02-12 2008-08-21 Mclendon George L IAP-binding cargo molecules and peptidomimetics for use in diagnostic and therapeutic methods
US7135575B2 (en) 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
US7932382B2 (en) * 2004-01-16 2011-04-26 The Regents Of The University Of Michigan Conformationally constrained Smac mimetics and the uses thereof
WO2005069888A2 (en) 2004-01-16 2005-08-04 The Regents Of The University Of Michigan Smac peptidomimetics and the uses thereof
WO2005074989A2 (en) 2004-02-05 2005-08-18 Novartis Ag Combination of a dna topoisomerase inhibitor and an iap inhibitor
US20070217607A1 (en) 2004-02-15 2007-09-20 Matrixview Limited Repetition Coded Compression For Encrypting Highly Correlated Data
US7309792B2 (en) 2004-03-01 2007-12-18 Board Of Regents, The University Of Texas System Dimeric small molecule potentiators of apoptosis
WO2005094818A1 (en) 2004-03-23 2005-10-13 Genentech, Inc. Azabicyclo-octane inhibitors of iap
SG152225A1 (en) 2004-04-07 2009-05-29 Novartis Ag Inhibitors of iap
US7244851B2 (en) 2004-07-02 2007-07-17 Genentech, Inc. Inhibitors of IAP
JP4828840B2 (ja) 2004-07-08 2011-11-30 パナソニック株式会社 表示パネルの駆動方法
WO2006010118A2 (en) 2004-07-09 2006-01-26 The Regents Of The University Of Michigan Conformationally constrained smac mimetics and the uses thereof
EP1773348A4 (en) 2004-07-12 2009-05-20 Idun Pharmaceuticals Inc TETRA PEPTIDE ANALOGS
ES2475207T3 (es) 2004-07-15 2014-07-10 Tetralogic Pharmaceuticals Corporation Compuestos de unión a IAP
DK1836201T4 (da) 2004-12-20 2013-11-11 Genentech Inc Pyrrolidininhibitorer af IAP.
CN103083644B (zh) * 2005-02-25 2014-05-28 泰特拉洛吉克药业公司 Iap二聚体抑制剂
US20070003535A1 (en) 2005-03-17 2007-01-04 Reed John C Methods and compositions for derepression of IAP-inhibited caspase
EP1883627B1 (en) 2005-05-18 2018-04-18 Pharmascience Inc. Bir domain binding compounds
WO2006128455A2 (en) 2005-05-25 2006-12-07 2Curex Aps Compounds modifying apoptosis
MX2007015419A (es) 2005-06-08 2008-02-21 Novartis Ag Compuestos organicos.
WO2007021825A2 (en) * 2005-08-09 2007-02-22 Tetralogic Pharmaceuticals Corporation Treatment of proliferative disorders
US20070203749A1 (en) 2005-08-09 2007-08-30 Sri Chunduru Business methods for compounds for treatment of proliferative disorders
AU2006308453B9 (en) 2005-10-25 2011-12-01 Pharmascience Inc. IAP BIR domain binding compounds
EP1973899A4 (en) 2005-12-19 2010-10-20 Genentech Inc HEMMER OF IAP
MX2008008191A (es) * 2005-12-20 2008-11-04 Novartis Ag Combinacion de un inhibidor iap y un taxano 7.
WO2007101347A1 (en) 2006-03-07 2007-09-13 Aegera Therapeutics Inc. Bir domain binding compounds
TWI504597B (zh) * 2006-03-16 2015-10-21 Pharmascience Inc 結合於細胞凋亡抑制蛋白（ｉａｐ）之桿狀病毒ｉａｐ重複序列（ｂｉｒ）區域之化合物
US7807699B2 (en) * 2006-03-21 2010-10-05 Joyant Pharmaceuticals, Inc. Dimeric pyrrolidine amide-containing small molecule apoptosis promoters
US8202902B2 (en) * 2006-05-05 2012-06-19 The Regents Of The University Of Michigan Bivalent SMAC mimetics and the uses thereof
KR101071516B1 (ko) 2006-05-05 2011-10-10 더 리젠츠 오브 더 유니버시티 오브 미시간 2가 ｓｍａｃ 모방체 및 그의 용도
NZ572836A (en) * 2006-05-16 2011-12-22 Pharmascience Inc Iap bir domain binding compounds
AR064235A1 (es) 2006-07-24 2009-03-25 Tetralogic Pharmaceuticals Cor Dipeptidos antagonistas de iap, una composicion farmaceutica que los comprende y el uso de los mismos para el tratamiento del cancer
AU2007276760B2 (en) 2006-07-24 2012-01-19 Tetralogic Pharmaceuticals Corporation Dimeric IAP antagonists
PE20080951A1 (es) 2006-08-02 2008-09-11 Novartis Ag DERIVADOS DE 2-OXO-ETIL-AMINO-PROPIONAMIDA-PIRROLIDIN-2-IL-SUSTITUIDOS COMO INHIBIDORES DEL ENLACE DE LA PROTEINA Smac AL INHIBIDOR DE LA PROTEINA DE APOPTOSIS
MX2009004061A (es) 2006-10-19 2009-04-27 Novartis Ag Compuestos organicos.
WO2008079735A1 (en) * 2006-12-19 2008-07-03 Genentech, Inc. Imidazopyridine inhibitors of iap
MX2009010667A (es) * 2007-04-12 2010-02-24 Joyant Pharmaceuticals Inc Dimeros y trimeros mimeticos de smac utiles como agentes anti-cancer.
NZ580226A (en) 2007-04-30 2012-11-30 Genentech Inc Dimer compounds as inhibitors of iap
EP2328412A4 (en) 2008-09-17 2012-03-14 Tetralogic Pharm Corp IPA INHIBITORS
BRPI1011612A2 (pt) 2009-05-28 2019-09-24 Tetralogic Pharm Corp composto, composição farmacêutica, e, métodos para induzir apoptose em uma célula, para tratar câncer, e para tratar uma doença autoimune.
JP5631387B2 (ja) 2009-05-28 2014-11-26 テトラロジック ファーマシューティカルズ コーポレーション Ｉａｐ阻害剤
US8283372B2 (en) 2009-07-02 2012-10-09 Tetralogic Pharmaceuticals Corp. 2-(1H-indol-3-ylmethyl)-pyrrolidine dimer as a SMAC mimetic

Also Published As

Publication number Publication date
PL1851200T3 (pl) 2014-06-30
CN103083644B (zh) 2014-05-28
EA200701597A1 (ru) 2008-02-28
US20160355547A1 (en) 2016-12-08
US20110301151A1 (en) 2011-12-08
US8497297B2 (en) 2013-07-30
AU2006216450B2 (en) 2011-12-22
US8822525B2 (en) 2014-09-02
EA012810B1 (ru) 2009-12-30
AU2006216450C1 (en) 2013-01-10
CA2598995C (en) 2014-07-15
US20060194741A1 (en) 2006-08-31
JP5198880B2 (ja) 2013-05-15
US9920093B2 (en) 2018-03-20
KR20080013855A (ko) 2008-02-13
US7517906B2 (en) 2009-04-14
EP1851200B1 (en) 2014-01-15
HK1118044A1 (en) 2009-01-30
WO2006091972A2 (en) 2006-08-31
AU2006216450A1 (en) 2006-08-31
US9187490B2 (en) 2015-11-17
MX2007010371A (es) 2008-01-11
WO2006091972A3 (en) 2006-10-05
CY1115972T1 (el) 2017-01-25
BRPI0607988A2 (pt) 2009-10-27
IL185454A0 (en) 2008-01-06
EP2385038A1 (en) 2011-11-09
CA2598995A1 (en) 2006-08-31
US20160052965A1 (en) 2016-02-25
ES2456671T3 (es) 2014-04-23
EP1851200A2 (en) 2007-11-07
IL185454A (en) 2013-01-31
US8022230B2 (en) 2011-09-20
US20100075911A1 (en) 2010-03-25
DK1851200T3 (da) 2014-04-14
JP2008531601A (ja) 2008-08-14
US20130289042A1 (en) 2013-10-31
US20140329823A1 (en) 2014-11-06
KR101317661B1 (ko) 2013-10-15
CN103083644A (zh) 2013-05-08

Similar Documents

Publication Publication Date Title
IL185454A0 (en) Dimeric iap inhibitors
ZA200805152B (en) Inhibitors of IAP
IL196423A0 (en) Dimeric iap antagonists
ZA200707650B (en) Azolylacylguanidines as ß-secretase inhibitors
IL201379A0 (en) Inhibitors iap
EP2030513A4 (en) SALT TASTE AMPLIFIERS
EP1971595A4 (en) CETP INHIBITORS
EP1973889A4 (en) CETP INHIBITORS
HUS2000022I1 (hu) Tiglien-3-on származékok
EP1878727A4 (en) 2-AMINOQUINAZOLINE DERIVATIVES
IL192092A0 (en) Aryl-isoxazolo-4-yl-oxadiazole derivatives
IL185674A0 (en) 1-benzylindole-2-carboxamide derivatives
IL189048A0 (en) Gsk-3 inhibitors
ZA200802088B (en) 4-Phenyl-6-substitued-pyrimidine-2-carbonitrile derivatives
ZA200802421B (en) 1-Acyldihydropyrazol derivatives
ZA200804257B (en) Azaindole-2-carboxamide derivatives
ZA200805353B (en) Aryl-isoxazol-4-yl-imidazole derivatives
ZA200805386B (en) MIF inhibitors
EP1951053A4 (en) CETP INHIBITORS
ZA200707023B (en) Dimeric IAP inhibitors
IL191138A0 (en) Pyrazoloisoquinoline derivatives
EP2028250A4 (en) luminescence enhancer
GB0511410D0 (en) Benzotrizepinone derivatives
GB0516967D0 (en) Inhibitors
ZA200706577B (en) Dihydroimidazothiazole derivatives

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20240227